1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsNo specific application deadline listed on the page; program is actively issuing awards as of March 2026.
Complement Animal Research in Experimentation (Complement-ARIE) program is sponsored by National Institutes of Health (NIH). Supports the development and scaling of research methods that better simulate human biology and reduce reliance on animal models.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Complement Animal Research In Experimentation (Complement-ARIE) Program | NIH Common Fund Complement Animal Research In Experimentation (Complement-ARIE) Program Complement Animal Research In Experimentation (Complement-ARIE) Program The NIH Common Fund’s Complement Animal Research In Experimentation (Complement-ARIE) program will speed the development, standardization, validation, and use of human-based New Approach Methodologies (NAMs).
NAMs are lab or computer-based research approaches intended to more accurately model human biology, and complement, or in some cases, replace traditional research models. The Complement-ARIE program will build upon ongoing efforts related to NAMs, while identifying opportunities for innovation and coordination.
Complement-ARIE will significantly advance understanding of human health and disease by providing a range of ready and standardized biomedical research models. Developing these models will require expertise in disease research, personalized medicine, and in screening therapeutics for safety and effectiveness.
Complement-ARIE will bring these expertise together through a consortium of researchers participating in the following efforts: Technology development projects/centers that will develop NAMs to fill in areas of greatest need. Projects will emphasize biological complexity, high throughput techniques, combining approaches, and data sharing.
A data & NAM resource coordinating center that will create integrated data structures and a searchable NAMs repository. A validation network that will accelerate deployment and regulatory approval of NAMs for biomedical research. Community engagement and training that will promote the development of an inclusive, diverse, biomedical research workforce with the skills to build and use new NAMs.
Strategic engagement with key partners that will advance emerging opportunities in development and use of NAMs in basic, translational, and clinical research. To learn more about related work being done at NIH, visit: NIH NCATS Tissue Chip for Drug Screening Program Have a question? Reach out to us at [email protected] Complement-ARIE has launched new awards that will revolutionize new approach methodologies!
The Complement-ARIE Validation and Qualification Network public private partnership, managed by the Foundation for NIH, has announced the selection of four innovative research platforms for development into pilot projects. Complement-ARIE launched the $7,000,000 Reduction to Practice Prize on September 30th! Join this exciting challenge to bring your integrated New Approach Methods to validation.
On July 24th, the Foundation for NIH announced that more than 40 government, life science, nonprofit, and regulatory organizations have joined the Validation and Qualification Network (VQN) public private partnership. The FDA announced April, 10, 2025 that it would be immediately moving forward with a roadmap to reduce animal testing in preclinical safety studies with scientifically validated new approach methodologies (NAMs).
This roadmap calls for continued and closer collaboration with the NIH Complement-ARIE Program. On January 25, 2024, The NIH Council of Councils approved the concept of the NIH Common Fund's Complement Animal Research In Experimentation (Complement-ARIE) Program. Find out more by browsing the presentation slides and program description.
Or watch the videocast. The NIH Director released a statement on catalyzing the development of NAMs. This page last reviewed on
According to the current listing, eligibility includes: Research teams across the United States. Confirm the full requirements in the official notice before applying.
The current listing shows more than $150 million in total. Verify award ceilings, matching requirements, and allowable costs in the official notice.
Complement Animal Research in Experimentation (Complement-ARIE) program is funded by National Institutes of Health (NIH). Verify program details on the funder's official page before applying.
Yes — this listing is flagged as national in scope, so applicants across the U.S. may apply, subject to the sponsor's other eligibility criteria.
Applications go through the funder's official portal — the Apply Now link on this page goes there directly.
PA-27-037 consolidates the Predoctoral to Postdoctoral Transition Award into a single parent announcement across 20 NIH components, with the next deadline December 8, 2026. The eligibility gate is not the science — it is a mandatory change of institution and mentor between the F99 and K00 phases.
Read articleA draft executive order would have put OMB Director Russell Vought on a commission with final say over NIH awards after peer review. Sen. Collins killed it by pointing at a provision Congress already passed. Here is what the episode teaches applicants about the December 11 cliff.
Read articlePA-27-034, PA-27-035 and PA-27-036 replace the institute-specific R25 announcements that research education programs have been built around for a decade. NCI, NIDA and NIGMS have already expired theirs early. Here is what the consolidation actually changes: an 8% indirect cost ceiling, a US-citizens-and-permanent-residents participant rule, a cooperative agreement variant that only exists on one of the three, and no clinical-trial-allowed companion anywhere.
Read article